首页> 美国卫生研究院文献>Therapeutic Advances in Gastroenterology >Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study

【2h】

Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study

机译：与其他适应症相比使用硫疗症患者恶性肿瘤患者的风险：全国范围内的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Thiopurines are believed to increase cancer risks, but data from Asian patients are sparse. We determined the risks of malignancies in thiopurine users with inflammatory bowel disease (IBD) or other indications from Hong Kong.

机译：据信硫嘌呤增加癌症风险，但亚洲患者的数据很少。我们确定了硫嘌呤用户的恶性肿瘤风险，炎症肠病（IBD）或香港的其他适应症。

著录项

期刊名称 Therapeutic Advances in Gastroenterology
作者
Kelvin Y. C. Zheng; Chuan-Guo Guo; Irene O. L. Wong; Lijia Chen; Ho Yin Chung; Ka Shing Cheung; Wai K. Leung;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词

机译：炎症性肠病;恶性;硫嘌呤;

相似文献

外文文献
中文文献
专利

1. Immunosuppression increases the risk of lymphoproliferative diseases in chronic inflammatory bowel diseases: In a French prospective cohort study, a considerably increased relative risk of developing lymphoprolative diseases in patients with chronic inflammatory bowel diseases under therapy with thiopurines is manifested [J] . Medizinische Klinik . 2010,第6期

机译：免疫抑制会增加慢性炎症性肠病中淋巴增生性疾病的风险：在法国的一项前瞻性队列研究中，在用硫嘌呤治疗的慢性炎症性肠病患者中，发展成淋巴结性疾病的相对风险显着增加
2. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies [J] . BeigelF., SteinbornA., SchnitzlerF., Pharmacoepidemiology and drug safety . 2014,第7期

机译：用硫嘌呤或抗TNFα抗体治疗的炎症性肠病患者发生恶性肿瘤的风险
3. Risk of skin cancers in thiopurines‐treated and thiopurines‐untreated patients with inflammatory bowel disease: A systematic review and meta‐analysis [J] . Huang Shao‐Zhuo, Liu Zhi‐Cheng, Liao Wei‐Xin, Journal of gastroenterology and hepatology . 2019,第3期

机译：硫嘌呤治疗和硫嘌呤 - 未经处理的炎症性肠病患者皮肤癌的风险：系统审查和荟萃分析
4. Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases [C] . J.-F. COLOMBEL, M. TORUNE Falk Symposium . 2007

机译：炎症性肠病患者的发病率增加了与免疫调节治疗有关的发病危险
5. A study of risk factors associated with inflammatory bowel disease. [D] . Gibson, Tony S. 2017

机译：与炎症性肠病相关的危险因素的研究。
6. Use of Thiopurines and Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Diseases: A Meta-Analysis [O] . Jianfeng Gong, Lijing Zhu, Zhen Guo, -1

机译：硫代嘌呤类药物的使用和大肠炎患者大肠肿瘤的风险：一项荟萃分析
7. Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study [O] . Kelvin Y. C. Zheng, Chuan-Guo Guo, Irene O. L. Wong, 2020

机译：与其他适应症相比，使用硫疗症患者恶性肿瘤患者的风险：全国范围内的研究

Risk of malignancies in patients with inflammatory bowel disease who used thiopurines as compared with other indications: a territory-wide study

摘要

著录项

相似文献

相关主题

期刊订阅